The short version of growth hormone fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-24. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
=== EC 1.4.3 With oxygen as acceptor === EC 1.4.3.1: D-aspartate oxidase EC 1.4.3.2: L-amino-acid oxidase EC 1.4.3.3: D-amino-acid oxidase EC 1.4.3.4: monoamine oxidase EC 1.4.3.5: pyridoxal 5′-phosphate synthase EC 1.4.3.6: replaced by two enzymes, EC 1.4.3.21 (primary-amine oxidase) and EC 1.4.3.22 (diamine oxidase) EC 1.4.3.7: D-glutamate oxidase EC 1.4.3.8: ethanolamine oxidase EC 1.4.3.9: Now included with EC 1.4.3.4 amine oxidase (flavin-containing) EC 1.4.3.10: putrescine oxidase EC 1.4.3.11: L-glutamate oxidase EC 1.4.3.12: cyclohexylamine oxidase EC 1.4.3.13: protein-lysine 6-oxidase EC 1.4.3.14: L-lysine oxidase EC 1.4.3.15: D-glutamate(D-aspartate) oxidase EC 1.4.3.16: L-aspartate oxidase EC 1.4.3.17: Now EC 1.3.3.10, tryptophan α,β-oxidase EC 1.4.3.18: Not approved as the enzyme was shown to be a dehydrogenase and not an oxidase (see EC 1.5.99.12, cytokinin dehydrogenase) EC 1.4.3.19: glycine oxidase EC 1.4.3.20: L-lysine 6-oxidase EC 1.4.3.21: primary-amine oxidase EC 1.4.3.22: diamine oxidase EC 1.4.3.23: 7-chloro-L-tryptophan oxidase EC 1.4.3.24: Now EC 1.4.2.3, pseudooxynicotine oxidase EC 1.4.3.25: L-arginine oxidase EC 1.4.3.26: pre-mycofactocin synthase
Placing flat hands on the floor with straight legs Left knee bending backward Right knee bending backward Left elbow bending backward Right elbow bending backward Left thumb touching the forearm Right thumb touching the forearm Left little finger bending backward past 90 degrees Right little finger bending backward past 90 degrees
In sensory neurons, action potentials result from an external stimulus. However, some excitable cells require no such stimulus to fire: They spontaneously depolarize their axon hillock and fire action potentials at a regular rate, like an internal clock. The voltage traces of such cells are known as pacemaker potentials. The cardiac pacemaker cells of the sinoatrial node in the heart provide a good example. Although such pacemaker potentials have a natural rhythm, it can be adjusted by external stimuli; for instance, heart rate can be altered by pharmaceuticals as well as signals from the sympathetic and parasympathetic nerves. The external stimuli do not cause the cell's repetitive firing, but merely alter its timing. In some cases, the regulation of frequency can be more complex, leading to patterns of action potentials, such as bursting.
Sources: en.wikipedia.org
O-Linked glycans are formed by a linkage between an amino acid hydroxyl side chain (usually from serine or threonine) with the glycan. The majority of O-linked glycans take the form GlcNac-β-Ser/Thr or GalNac-α-Ser/Thr.
=== Off-label drugs === Alcohol (over-the-counter self-medication) – GABAA receptor positive allosteric modulator Atypical antipsychotics (e.g., olanzapine, quetiapine) – monoamine receptor modulators Benzodiazepines (e.g., alprazolam, chlordiazepoxide, clonazepam, diazepam, lorazepam, oxazepam) – GABAA receptor positive allosteric modulators Beta blockers (e.g., atenolol, propranolol) – β-adrenergic receptor antagonists Bupropion (Wellbutrin) – norepinephrine–dopamine reuptake inhibitor (NDRI) and nicotinic acetylcholine receptor negative allosteric modulator Cannabidiol (CBD) – cannabinoid receptor modulator and other actions, found in cannabis Gabapentinoids (e.g., gabapentin, pregabalin) – α2δ subunit-containing voltage-dependent calcium channel blockers Monoamine oxidase inhibitors (MAOIs) (e.g., phenelzine, selegiline, tranylcypromine) NMDA receptor antagonists (e.g., ketamine) Other anticonvulsants (besides gabapentinoids) (e.g., topiramate, valproic acid, tiagabine) Psychostimulants (e.g., amphetamine, methylphenidate) Selective serotonin reuptake inhibitors (SSRIs) (non-licensed) (e.g., citalopram, fluoxetine) Serotonin–norepinephrine reuptake inhibitors (SNRIs) (non-licensed) (e.g., desvenlafaxine, duloxetine) Serotonin 5-HT1A receptor agonists (e.g., buspirone) Tricyclic antidepressants (TCAs) (e.g., clomipramine, imipramine)
==== Drugs ==== Sipuleucel-T (Provenge) was approved for treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer in 2010. The treatment consists of removal of antigen-presenting cells from blood by leukapheresis and growing them with the fusion protein PA2024 made from GM-CSF and prostate-specific prostatic acid phosphatase (PAP) and reinfused. This process is repeated three times.
Sources: en.wikipedia.org
=== 1959 === January 1: Fidel Castro wins the Cuban Revolution and becomes the dictator of Cuba. In the next several years Cuban-inspired guerrilla movements spring up across Latin America. January 2: Luna 1 is launched in an attempt to impact the Moon but due to an error in device's control systems, resulted in the device missing its target by 5,990 kilometres (3,720 mi). March 3: Pioneer 4 was launched in an attempt to photograph the Moon. The probe failed to achieve its intended target of 32,000 kilometres (20,000 mi) from the Moon, reaching only 60,000 kilometres (37,000 mi), too distant for its scanners to photograph the Moon. March 10–23: The Tibetan uprising occurs. March 24: New Republic government of Iraq leaves Central Treaty Organization. May 23: The Laotian Civil War begins. July 24: During the opening of the American National Exhibition in Moscow US Vice President Richard Nixon and Soviet First Secretary Khrushchev openly debate the capacities of each Superpower. This conversation is known as the Kitchen Debate. July 31: The Basque conflict officially begins, with the aim of creating an independent state for the Basque people. August 7: Explorer 6 is launched into orbit to photograph the Earth. September: Khrushchev visits U.S. for 13 days, and is denied access to Disneyland. Instead, he visits SeaWorld (then known as Marineland of the Pacific). September 13: Luna 2 is launched and becomes the first man-made object to reach the surface on the Moon. October 4–22: Luna 3 is launched to take photographs of the far side of the Moon.
The Detroit Riverfront, for instance, is maintained and developed almost exclusively through nonprofit funding in partnership with public and private enterprises. This model for economic development and revitalization has seen enormous success in Detroit, with the Detroit Riverfront Conservancy raising in excess of $23 million to revitalize and maintain riverfront assets. This model for economic development is so promising that the city has turned to similar partnership strategies to manage, maintain, and revitalize several other city assets. Over the past seventy years, the city of Detroit has experienced a dramatic reduction in its population and economic well-being. This decline has left countless community members in economic turmoil, driving many residents to fall behind on taxes and subject their homes to tax foreclosure. Due to the overassessment of property values based on outdated appraisals, the property taxes on these homes are massively inflated, perpetuating further property foreclosure and community displacement. These foreclosed properties are often turned over to a public auction, where many of them are purchased by wealthy investors looking to take advantage of Detroit's housing market. Proponents of such investment argue that wealthy investors have minimized displacement by redeveloping vacant areas where people did not reside; however, this kind of investment can have additional repercussions beyond residents' physical and economic displacement.
Internal medicine, also known as general medicine in Commonwealth nations, is a specialty for medical doctors focused on the prevention, diagnosis, and treatment of diseases in adults. Internal refers to the "treatment of diseases of the internal organs". Practitioners of internal medicine are referred to as internists in North America and physicians in Britain and most Commonwealth nations. Internists possess specialized skills in managing patients with undifferentiated or multi-system disease processes. They provide care to both hospitalized (inpatient) and ambulatory (outpatient) patients, as their patients are frequently seriously ill or require extensive medical tests. Internists often have subspecialty interests in diseases affecting particular organs or organ systems, and often contribute significantly to teaching and research. The certification process and available subspecialties may vary across different countries. Internists are qualified doctors who have undergone postgraduate training in internal medicine, and should not be confused with "interns", a term commonly used for a doctor who has obtained a medical degree but does not yet have a license to practice medicine unsupervised. There is also sometimes confusion between internal medicine and family medicine, with people mistakenly considering them equivalent. Internal medicine is also recognized as a specialty within clinical pharmacy and veterinary medicine.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.